Market Size of Creatine Kinase Reagent Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 5.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Creatine Kinase Reagent Market Analysis
The creatine kinase reagent market is anticipated to register a CAGR of nearly 5.5% during the forecast period.
- The COVID-19 pandemic had a profound impact on the creatine kinase reagent market. For instance, as per the NLM's article published in May 2021, increased creatine kinase was reported in 9% - 33% of patients with COVID-19. Skeletal muscle injury and myopathies in COVID-19 were associated with increased neutrophils, lymphopenia, C-reactive protein (CRP), increased D-dimer levels, length of ICU stay, and more severe disease.
- Myositis, a subset of myopathy due to inflammation of muscle fibers, has also been reported in patients with COVID-19 in association with elevated creatine kinase values. This, in association with findings of elevated inflammatory cytokines, has led to the hypothesis that COVID-19-induced myopathy may result from the inflammatory cascade. Hence, the pandemic had a negligible impact on the creatine kinase reagent market.
- In addition, the increasing prevalence of cardiovascular diseases and muscular injuries and diseases are actively affecting the growth of the studied market. For instance, according to the World Health Organization (WHO) June 2021 report, cardiovascular disease, which caused an estimated 17.9 million fatalities and 32% of all deaths globally in 2020, is the most common type of chronic disease.
- Also, according to the Australian Bureau of Statistics, an estimated 571,000 Australians aged 18 and over (2.9% of the adult population) had chronic heart diseases in 2021. Hence, the country's high burden of cardiovascular diseases is projected to boost the market growth.
- Furthermore, an article published in Neuroepidemiology Journal in July 2021 stated that combined prevalence rates (per 100,000 people) and incidence rates (per 100,000 person-years) for amyotrophic lateral sclerosis (ALS) were 6.22 and 2.31 for Europe, 5.20 and 2.35 for North America, 3.41 and 1.25 for Latin America, 3.01 and 0.93 for Asian countries excluding Japan, and 7.96 and 1.76 for Japan respectively in 2021.
- Since creatine kinase is used as a marker of muscle damage and is significantly elevated in people with ALS, it is widely used in diagnosing this neurological disease. Hence, the high burden of ALS is projected to boost market growth during the forecast period.
- However, the global market for creatine kinase reagents may be constrained by the strict regulatory frameworks for qualification processes that evaluate companion diagnostics of creatine kinase.
Creatine Kinase Reagent Industry Segmentation
As per the scope of the report, creatine kinase is an enzyme found in skeletal muscle, heart muscle, and brain. It is the best-known marker for identifying various cardiovascular diseases and muscle injuries/diseases.
The creatine kinase reagent market is segmented by product (reagents and instruments), application (acute myocardial infarction, congestive heart failure, acute coronary syndrome, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions.
The report offers the value (in USD million) for the above segments.
By Product | |
Reagents | |
Instruments |
By Application | |
Acute Myocardial Infarction (AMI) | |
Congestive Heart Failure (CHF) | |
Acute Coronary Syndrome (ACS) | |
Other Applications |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Creatine Kinase Reagent Market Size Summary
The creatine kinase reagent market is poised for steady growth, driven by the increasing prevalence of cardiovascular diseases and muscular injuries. The market's expansion is supported by the rising incidence of conditions such as acute coronary syndrome and amyotrophic lateral sclerosis, where creatine kinase serves as a crucial diagnostic marker. The COVID-19 pandemic, while initially impacting the market, has underscored the importance of creatine kinase in understanding muscle damage and inflammation associated with the virus. The market is further bolstered by the aging population, particularly in regions like Sub-Saharan Africa and Asia, where the elderly are more susceptible to chronic ailments requiring regular monitoring and diagnosis.
North America stands out as a significant market due to its robust healthcare infrastructure and the high prevalence of cardiovascular diseases. The region's well-established pharmaceutical and research sectors contribute to the market's growth, with companies like Abbott Laboratories and Thermo Fisher Scientific leading the charge through strategic initiatives such as mergers and acquisitions. Despite the competitive landscape, characterized by both global and local players, the market is expected to thrive, driven by technological advancements and the continuous demand for effective diagnostic solutions. The regulatory environment, while stringent, is navigated by key players through innovation and compliance, ensuring sustained market presence and growth.
Creatine Kinase Reagent Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Cardiovascular Diseases
-
1.2.2 Rising Prevalence of Muscular Injuries and Diseases
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Framework for Qualification Processes that Evaluate Companion Diagnostics of Creatine Kinase
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Product
-
2.1.1 Reagents
-
2.1.2 Instruments
-
-
2.2 By Application
-
2.2.1 Acute Myocardial Infarction (AMI)
-
2.2.2 Congestive Heart Failure (CHF)
-
2.2.3 Acute Coronary Syndrome (ACS)
-
2.2.4 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Creatine Kinase Reagent Market Size FAQs
What is the current Creatine Kinase Reagent Market size?
The Creatine Kinase Reagent Market is projected to register a CAGR of 5.5% during the forecast period (2024-2029)
Who are the key players in Creatine Kinase Reagent Market?
Abbott, Danaher Corporation (Beckman Coulter, Inc.), BBI Solutions, DiaSys Diagnostic Systems GmbH and BODITECH MED INC are the major companies operating in the Creatine Kinase Reagent Market.